Opioid peptide response to spinal cord stimulation in chronic critical limb ischemia.

Dipartimento di Medicina Interna, Cardioangiologia, Epatologia, Ospedale S. Orsola, Via Massarenti 9, 40138 Bologna, Italy.
Peptides (Impact Factor: 2.61). 04/2004; 25(4):571-5. DOI: 10.1016/j.peptides.2004.01.007
Source: PubMed

ABSTRACT Twelve patients with chronic critical limb ischemia in whom a spinal cord stimulation (SCS) system had been implanted for at least one year had increased microvascular flow and achieved healing of trophic acral lesions. After switching off the system, the clinical improvement persisted for 10 days and the neurohormonal pattern showed high plasma values of beta-endorphin and Met-enkephalin, normal dynorphin B, endothelin-1 and catecholamines, and low nitric oxide. Met-enkephalin levels were further increased (P < 0.01) immediately after switching on the electrical stimulation again. The persistence of high plasma opioid levels after switching off the spinal cord stimulation explains the absence of subjective complaints and suggests an involvement of opioids in the regulation and improvement of the microcirculation.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The present study investigated changes in the met-enkephalin (M-ENK) levels in the spinal cord. We also determined the mechanical threshold value of pain in spared nerve injury (SNI) rats after applying pulsed radiofrequency (PRF) on L5 dorsal root ganglion (DRG). Sixty-four rats were divided into four groups: the normal group (n = 16), the control group (n = 16), the sham intervention group (n = 16), and the PRF group (n = 16). With exception for the normal group, the other three groups were treated with an established SNI model. After 7 days, PRF or sham intervention was applied on the right L5 DRG. The M-ENK levels in the spinal cord were examined by radioimmunoassay 24 hours after applying PRF or sham operation. Mechanical threshold values of pain were also tested 1 day before SNI procedure, 1 and 2 days after SNI procedure, and 2 and 24 hours after applying PRF or sham operation. Twenty-four hours after treatment with PRF, M-ENK levels in spinal cord increased significantly, while no changes were detected in the sham intervention group. Hyperalgesia was found in rats 1-2 days after SNI procedure and was improved by PRF. This was demonstrated by an increased mechanical threshold of pain 2 and 24 hours after the PRF. The sham intervention group showed no change in the mechanical threshold of pain. This study demonstrates that applying PRF on the DRG can improve hyperalgesia and increase M-ENK levels in the spinal cord of SNI rats within 24 hours. These findings indicate that the endogenous M-ENK in the spinal cord is involved in the mechanism of PRF on the therapy of neuropathic pain.
    Neurological Research 05/2012; 34(4):408-14. DOI:10.1179/1743132812Y.0000000026 · 1.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We studied circulating levels of endothelin-1, catecholamines and nitric oxide after a mental arithmetic test in 14 patients with early ischemic lesions of the extremities due to systemic sclerosis and slightly impaired peripheral vascular flow. The test induced an increase (P<0.01) in blood pressure, heart rate, endothelin-1 and catecholamine levels, whereas it did not change the low basal levels of nitric oxide. In healthy subjects (n=20) the test significantly (P<0.01) decreased endothelin-1 without affecting nitric oxide. The low basal levels of nitric oxide and the high plasma concentration of endothelin-1 after psychological stress cannot be explained by an impaired release from the limited ischemic lesions alone. This suggests a diffuse microvascular derangement that aggravates the course of peripheral microvascular ischemic lesions.
    Peptides 12/2005; 26(12):2487-90. DOI:10.1016/j.peptides.2005.06.001 · 2.61 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Spinal cord stimulation (SCS) is an effective treatment for neuropathic pain, but its effect on chronic muscle pain is unclear. We designed this study to test the effect of SCS in an animal model of noninflammatory muscle pain. Male Sprague-Dawley rats were implanted with an epidural SCS lead on the upper lumbar spinal cord (L3-L4) under isoflurane anesthesia (4%). Ten days after implantation, chronic muscle pain was induced by giving 2 injections of pH 4 saline into the left gastrocnemius muscle, 5 days apart. In experiment 1, SCS was delivered daily (6-hour duration/day) for 4 days at one of 4 different frequencies (0 (sham), 4, 60, and 100 Hz) from day 6 to day 9. Paw withdrawal threshold and muscle withdrawal threshold were measured before the first injection, and before and during SCS daily. Physical activity (distance, crossing, stand, and grooming) was assessed before the first injection, before SCS on day 6 and during SCS on day 9. In experiment 2, SCS was delivered (6 hours) on day 6 at either 60 or 100 Hz. Paw withdrawal threshold and muscle withdrawal threshold were assessed before the first injection, before and during SCS on day 6, and daily for the following 3 days (day 7-day 9). Paw withdrawal threshold and muscle withdrawal threshold significantly decreased bilaterally after the second injection of acidic saline. SCS delivered at 60 or 100 Hz significantly reversed the decreased paw withdrawal threshold and muscle withdrawal threshold bilaterally when compared with that of sham SCS, but 4 Hz SCS had no effect on paw withdrawal threshold and muscle withdrawal threshold. SCS (60 or 100 Hz) delivered daily provided a persistently reversed effect, and SCS delivered singly provided a carryover effect for 24 hours. During 60 Hz SCS, the distance traveled and the number of crossings increased significantly when compared with that of sham SCS. The current study shows that higher frequencies of SCS (60 and 100 Hz) significantly reduce mechanical hyperalgesia of the paw and muscle in an animal model of noninflammatory muscle pain, and 60 Hz SCS restores physical activity levels of animals, not 4 Hz.
    Anesthesia and analgesia 05/2014; 119(1). DOI:10.1213/ANE.0000000000000239 · 3.42 Impact Factor